Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

8
433
1
32

Year Published

1980
1980
2010
2010

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 1,126 publications
(474 citation statements)
references
References 38 publications
8
433
1
32
Order By: Relevance
“…Compared to the evidence base for ulcerative colitis, the efficacy of sulfasalazine in Crohn's disease is less definitive and more dependent on location of disease activity [357,362,380,406]. The necessity for colonic bacterial azo-reductase activity to liberate 5-ASA implies that sulfasalazine is unlikely to benefit proximal (small intestinal) Crohn's disease and, in two early clinical trials evaluating more than 500 patients with active Crohn's disease sulfasalazine at dosages of 3-5 g/day were superior to placebo only for patients with ileocolonic or colonic disease but not for patients with disease confined to the small intestine [407,408]. Although sulfasalazine has been commonly used to prevent relapse for patients with quiescent Crohn's disease, neither the National Cooperative Crohn's Disease Study nor the European Cooperative Crohn's Disease Study demonstrated maintenance benefits at (low) dosages of 1-3 g/day.…”
Section: Aminosalicylates In Crohn's Disease Mild To Moderate Active mentioning
confidence: 99%
See 3 more Smart Citations
“…Compared to the evidence base for ulcerative colitis, the efficacy of sulfasalazine in Crohn's disease is less definitive and more dependent on location of disease activity [357,362,380,406]. The necessity for colonic bacterial azo-reductase activity to liberate 5-ASA implies that sulfasalazine is unlikely to benefit proximal (small intestinal) Crohn's disease and, in two early clinical trials evaluating more than 500 patients with active Crohn's disease sulfasalazine at dosages of 3-5 g/day were superior to placebo only for patients with ileocolonic or colonic disease but not for patients with disease confined to the small intestine [407,408]. Although sulfasalazine has been commonly used to prevent relapse for patients with quiescent Crohn's disease, neither the National Cooperative Crohn's Disease Study nor the European Cooperative Crohn's Disease Study demonstrated maintenance benefits at (low) dosages of 1-3 g/day.…”
Section: Aminosalicylates In Crohn's Disease Mild To Moderate Active mentioning
confidence: 99%
“…57.34). Dosed within a range of 0.25-0.75 mg/kg with subsequent taper after remission induction, prednisone or prednisolone were shown to be superior to placebo in both the National Cooperative Crohn's Disease Study [480] and the European Cooperative Crohn's Disease Study [408]. Studies of higher doses (1 mg/kg of prednisolone) showed superior remission rates, from roughly 60% to over 90% [241].…”
Section: Corticosteroids In Crohn's Disease Oral Corticosteroidsmentioning
confidence: 99%
See 2 more Smart Citations
“…Im Gesamtfiberblick liegt die Rate der erreichten Remissionen mit EN zwischen 50 und 70% und damit nicht wesentlich unter den M6glichkeiten der Kortikosteroidtherapie (bei Diinndarmbefall) aber auch nur etwas fiber der Gr613enordnung der spontanen Remissionen, die in multizentrischen Therapiestudien mit 40-60% angegeben wird [49,78,81].…”
Section: Enterale Erniihrungsmethodenunclassified